2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

655. Multiple Myeloma: Cellular Therapies: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Omics Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Quality of Care, Diseases, Infectious Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult
PAPER

4053 Infection risk with CAR T-cell therapy versus bispecific antibodies in relapsed/refractory multiple myeloma: A systematic review and meta-analysis

Rahul Khandekar, MD, MPH, Jason Avigan, MD2, Herman Van Besien, MD3, Faith Davies, MD4, Gareth Morgan, MD, PhD5, Sam Yamshon, MD6
1 NYU Grossman School of Medicine, New York, New York, United States
2 NYU Grossman School of Medicine, New York, New York, United States, Perlmutter Cancer Center, NYU Langone Health, New York, New York, United States
3 NYU Grossman School of Medicine, New York, New York, United States, Perlmutter Cancer Center, NYU Langone Health, New York, New York, United States
4 NYU Grossman School of Medicine, New York, New York, United States, Perlmutter Cancer Center, NYU Langone Health, New York, New York, United States
5 NYU Grossman School of Medicine, New York, New York, United States, Perlmutter Cancer Center, NYU Langone Health, New York, New York, United States
6 NYU Grossman School of Medicine, New York, New York, United States, Perlmutter Cancer Center, NYU Langone Health, New York, New York, United States

CAR T-cell therapy and bispecific antibodies have improved outcomes in relapsed/refractory multiple myeloma (RRMM), but infection remains a major cause of morbidity and mortality. In B-cell lymphoma, we previously showed that bispecifics have a higher rate of high-grade infection per patient-month relative to CAR T. While retrospective analyses suggest a similar pattern in RRMM, the relative rates of infection between CAR T and bispecific antibodies are not known.  

We systematically reviewed prospective clinical trials of FDA-approved CAR T or bispecific antibody therapy in RRMM through May 2026. Conference abstracts were excluded due to incomplete infection reporting. Because infection risk may differ by target antigen, we performed separate analyses including all products, then excluding GPRC5D-directed bispecifics. 

We assessed all-grade infection, grade 3–4 infection, and infection-related mortality. Outcomes were pooled using random-effects models as a proportion of patients experiencing an event, then indexed per 100 patient-months to control for duration of follow-up.  

14 studies including 1457 patients met criteria: 7 BCMA CAR T studies (n=813), 5 BCMA bispecific monotherapy studies (n=486), and 2 GPRC5D bispecific monotherapy studies (n=158). 

Including all bispecifics, no endpoint differed significantly from CAR T. All-grade infection was 0.72 (0.64–0.79) vs 0.67 (0.58–0.75) per patient (p = 0.36) and 4.48 (3.38–5.95) vs 3.76 (2.68–5.29) per 100 patient-months (p-m) (p = 0.44). Grade 3–4 infection was 0.31 (0.21–0.43) vs 0.24 (0.21–0.27) per patient (p = 0.22) and 1.85 (1.24–2.74) vs 1.35 (0.99–1.85) per 100 p-m (p = 0.23). Infection-related mortality was 0.06 vs 0.07 per patient (p = 0.74) and 0.35 vs 0.35 per 100 p-m (p = 0.98). 

When restricted to BCMA products, all-grade infection was numerically higher in bispecifics compared to CAR-T: 0.76 (0.71–0.80) vs 0.67 (0.58–0.75) per patient (p = 0.06) and 4.91 (3.96–6.08) vs 3.76 (2.68–5.29) per 100 p-m (p = 0.19) without reaching significance. Grade 3–4 infection was significantly higher with bispecifics at 0.37 (0.26–0.49) vs 0.24 (0.21–0.27) per patient (p = 0.03) and 2.46 (2.14–2.82) vs 1.35 (0.99–1.85) per 100 p-m (p < 0.01). Infection-related mortality did not differ, at 0.07 vs 0.07 per patient (p = 0.71) and 0.49 (0.35–0.67) vs 0.35 (0.20–0.61) per 100 p-m (p = 0.33). 

Since higher rates of grade 3–4 infection with bispecifics compared to CAR T were seen in the BCMA-only analysis but not when including GPRC5D bispecifics, we compared outcomes for BCMA vs GPRC5D bispecifics. All-grade infections were more common for BCMA than GPRC5D per patient: 0.76 (0.71–0.80) vs 0.59 (0.51–0.66; p < 0.01), but similar per 100 p-m: 4.91 (3.96–6.08) vs 3.49 (1.40–8.68, p = 0.48). Rate of grade 3–4 infection was higher at 0.37 (0.26–0.49) vs 0.17 (0.07–0.35) per patient (p = 0.06), and 2.46 (2.14 to 2.82) vs 0.79 (0.55 to 1.13) per 100 p-m (p < 0.01). Infection-related mortality was higher for BCMA at 0.07 (0.04–0.12) vs 0.02 (0.01–0.06) per patient (p = 0.04) and 0.49 (0.35–0.67) vs 0.10 (0.04–0.29) per 100 p-m(p < 0.01). 

BCMA bispecifics were associated with a significantly higher pooled rate of grade 3-4 infections than BCMA-directed CAR T therapies, both per patient and after adjustment for follow-up time, while all-grade infection and infection-related mortality were similar. This suggests that high-grade infection risk is a consideration when choosing between these modalities, highlighting the need for close surveillance during bispecific therapy.  

Analysis including GPRC5D bispecifics did not show any significant differences from CAR T, suggesting a lower degree of immunosuppression with talquetamab. Direct comparisons of bispecifics by target showed higher rates of all-grade, grade 3–4, and fatal infections with BCMA vs GPRC5D bispecifics and retained significance for grade 3–4 and fatal infections after correction for follow up. These results should be interpreted with caution given the small number of studies. 

Limitations include the small number of studies and variability in trial conduct, timing, and prophylaxis practices, and inconsistent infection reporting. 

Targeting BCMA, which unlike GPRC5D is expressed on mature and memory B cells as well as plasma cells, may have unique consequences for infection risk in T-cell-engaging therapies, and BCMA bispecifics may increase the risk of serious infection compared with CAR T.

Rahul Khandekar, MD, MPH: No relevant conflicts of interest to declare.